Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

CFO Joshua Smiley On Lilly’s Next Decade Of Growth

Strategy Includes Product-Specific Deals In $1bn Range

Jan 22 2021

• By Mandy Jackson

Growing bars graphic with rising arrow — Lilly expects to deliver "top-tier" growth through 2025 • Source: Shutterstock

Related Content

Lilly’s Paying $1.1bn For Itch Advantage With Dermira’s Lebrikizumab

Jan 10 2020

Lilly’s 2021 Double-Digit Growth Comes From COVID-19 Drugs, New Products

Dec 16 2020

Lilly's Tirzepatide Hits On Phase III, But Poised To Face A Crowded Diabetes Market

Dec 09 2020

Loxo Lays Out Plans For BTK Inhibitor LOXO-305 In CLL

Dec 07 2020

ESMO: A Tale Of Two CDK 4/6 Inhibitors With monarchE Success and Failure For PALLAS

Sep 21 2020

An Alzheimer’s Win: How Lilly Designed Donanemab Trial To Succeed

Jan 13 2021

Lilly Sees Positive Results With Next-Gen Alzheimer’s Drug Donanemab

Jan 12 2021

Related Companies

Eli Lilly and Company

Dermira Inc.

Prevail Therapeutics Inc.

Novo Nordisk A/S

Pfizer Inc.

Additional Topics

Growth Strategy Deals Business Strategies M & A Companies Commercial BioPharmaceutical

More from Business

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window